ACC.17 Advertising Opportunities - J....

ACC.17 DailyThe official daily newspaper of ACC.17, ACC’s 66th Annual Scientific Session & Expo

On-site issues published Friday, Saturday and Sunday.• Contains coverage of late-breaking science, keynote lectures and awards, and other

meeting highlights. Also includes daily schedule of key events

• Distributed daily at up to three leadership hotels and in marked bins located through-out the convention center

• Registration issue also distributed to all attendees in official meeting bags

Ad SizeB/W Page (3 issues)

Color Page (3 issues)

Full Page Ad $14,420 $21,115

Junior Page Ad $12,360 $18,540

Half Page Ad $9,270 $14,935(Horizontal or Vertical)

Quarter Page Ad $8,755 $14,420

Net agency commission

Premium Rates (3 issues)

Cover 4* $15,965

Cover 2* $13,905

Cover Tip** $21,115

Net agency commission

*Please note premium rates are in addition to B/W and Color charges listed above

**Per issue or $57,165 for all three on-site issues

• Drive traffic to your booth

• Showcase your products and services and make contact with key decision-makers

• Maximize your on-site effectiveness

ACC.17 Daily Publication Specs

Closing DatesACC.17 Daily Registration Issue Ad space . . . . . . . . .Jan. 25, 2017 Final ad artwork . . . Feb. 8, 2017

ACC.17 Daily Day 2 & 3 Ad space . . . . . . . . . Feb. 14, 2017 Final ad artwork . . March 1, 2017

Dates may differ for Cover Tipplease contact your account manager.

ACC.17 Daily Advertising Rates

Trisha Laramee [email protected]

Adam Sansolo [email protected]

ACC.17 AdvertisingOpportunities

WASHINGTON, DC

FRIDAYMARCH 17, 2017

ACC.17 Daily 66TH ANNUAL SCIENTIFIC

SESSION & EXPO

ACC.17 Opening Showcase Session and 2015 Simon Dack Lecture will take place today from 8:00 – 10:00 a.m. in Hall H (Main Tent)

Poppas

See LEARNING, page 1

New Future of CV Medicine Track Explores Technology Advancements ACC.17 will help prepare attendees for the future

of cardiovascular medicine with a first-of-its kind experience: the Future of Cardiovascular Medicine Track – a pathway that will showcase the current and future technology landscape.

“Cardiology is one of the specialties that is continually pushing the envelope in new medicines, technologies, and innovative methodologies to enhance team-based care,” says Rick Nishimura, MD, co-chair of the Track. “Technology will be at the center of the way that we all practice medicine in the future.”

This pathway will feature the latest developments for everyone with a role in cardiovascular medicine: providers, payers, academics and industry representatives. “Each of the 13 sessions could not be more different

– each module has its own focus, but all are cutting edge,” explains Sanjeev Bhavnani, MD, who will chair the ACC.17 session on Mobile Technology in Health Care today from 2 to 3:30 p.m. in

Room 20D. The

unifying question linking each forward-looking session aims to answer the question, “What will the future of cardiovascular medicine look like in 2025?” Along with new technologies, the sessions will feature innovation

EXPO DAILY & MAP

INCLUDED INSIDE!

ACC.17 Returns to the Nation’s Capital to Offer More Learning, Less Lecturing

M edical professionals from all over the world have returned to the Golden State for the ACC’s Annual Scientific Session and Expo (ACC.17),

which kicks off today. Following a mantra of “more learning, less lecturing,”

this year’s conference places a greater focus on more experiential opportunities for its attendees. The various new interactive and innovative learning environments include interviews, panel discussions, debates, moderated forums and small group talks, patient/physician role-playing, games and competitions and volunteer audience panelists.

“With each completed conference we have the benefit of looking at what works and what doesn’t for our attending members, building off our successes to make the

next meeting the best it can possibly be,” says Patrick T. O’Gara, MD, president of the ACC. “ACC.17

is easily the best version of this conference we’ve put together thus far – a culmination of things familiar, augmented and new, providing visitors

with a wholly unique experience across its three days of programming.”

O’Gara will help kick-off the meeting during the Opening Showcase Session at 8 a.m. in Hall H (Main Tent). The meeting will conclude on Monday


3 Today’s Schedule 4 Interview with ACC President 8 Critical Care Cardiology 12 Diabetes Research 13 HF Learning Pathway 18 International Symposiums

NCDR.17ACC’s annual conference for registry participants promotes further use of registry data and user engagement.

10 YEARS OF ACC MEMBER SECTIONSThe College is celebrating the 10 year anniversary of the Women in Cardiology Section.

DOVE LECTURERalph G. Brindis, MD, MPH will give the James T. Dove Lecture during today’s Practice Management and Leadership Intensive.

INSIDE

MORE6 2216

New Future of CV Medicine Track Explores Technology Advancements ACC.17 will help prepare

attendees for the future of cardiovascular medicine with a first-of-its kind experience: the Future of Cardiovascular Medicine Track – a pathway that will showcase the current and future technology landscape.

“Cardiology is one of the specialties that is continually pushing the envelope in new medicines, technologies, and innovative methodologies to enhance team-based care,” says Rick Nishimura, MD, co-chair of the Track. “Technology will be at the center of the way that we all practice medicine in the future.”

This pathway will feature the latest developments for everyone with a role in cardiovascular medicine: providers, payers, academics and industry representatives.

Download the free ACC.17 eMeeting Planner mobile app for the most up-to-

date information.


ACC.17 Opening Showcase Session and 2015 Simon Dack Lecture will take place today from 8:00 – 10:00 a.m. in Hall H (Main Tent)

Bleed Non-Bleed

Full Page Ad:

Trim Size: 10.625 x 15 in. 9.75 x 14.25 in.

Live Area: .375 in. inside trim .375 in. inside trim

Bleeds: .25 in. outside trim n/a

Junior Page Ad:

Trim Size: 7.5 x 10 in. 7 x 10 in.



Half Page Horizontal Ad:

Trim Size: 10.625 x 7.5 in. 9.75 x 7 in.



Half Page Vertical Ad:

Trim Size: 5 x 15 in 4.75 x 14.25 in.



Quarter Page Ad:

Trim Size: 5 x 7.25 in. 4.75 x 7 in.



Advertising & Sales OfficeAmerican Medical Communications

630 Madison Avenue, 2nd Floor Manalapan, NJ 07726732-490-5530Fax: 732-862-1116

ACCOUNT MANAGERS:Trisha [email protected]

Adam [email protected]

Jeffrey [email protected]

ACC.17 Expo DailyAt ACC.17, this publication places important Expo information directly in the hands of attendees. Inserted into the middle of the ACC.17 Daily newspaper, the ACC.17 Expo Daily is the only printed resource specifically highlighting ACC.17 exhibitors, Learning Destination partners and Prime Time Event hosts. The publication is smaller than the ACC.17 Daily newspaper (8.375 x 10.5”), increasing its visibility and encouraging attendees to pull it out and use as a reference while at the show.

Contents• Expo floor plan

• Exhibitor list alpha by company name

• Exhibitor list by booth number

• Stories highlighting that day’s Learning Destination and Prime Time Event programming, as well as general Expo highlights

Distribution• Distributed daily at up to three leadership hotels and in marked bins located

throughout the convention center

• Registration issue also distributed to all attendees in official meeting bags

ACC.17 Expo Daily Publication Specs

Full Page Ad $5,665

Half Page Horizontal Ad $3,605

Quarter Page Ad $2,060

Cover Ads (Bundle 2, 3, & 4) $36,565

ACC.17 Expo Daily Advertising Rates (Rates per day)

Digital File SpecificationsThe ACC.17 Daily, ACC.17 Expo Daily and NCDR.17 Registration Issue are produced and printed direct-to-plate (DTP). Below is the file format submission information for ads:

Submit ads as a high-resolution PDF with advertiser name and issue date in the filename following this format: CompanyName_Client/ProductName_AdSize_Day_Placement.pdf ex: AMC_Client/ProductName_FullPage_Sat_ACC.17ExpoDailyRob.pdf

PLEASE NOTE: ACC WILL REJECT ANY ADS WITH INCORRECT FILE FORMAT.

INTERNET/FTP DELIVERY OF ADS: Please email Ari Mihos ([email protected]) prior to submitting a file via FTP.

Address: 199.193.117.104Log in: cardiologyFTPPassword: Cardio1 Folder: cardiologyFTP/ACC.17_Daily

If desired, also email the PDF to Ari Mihos ([email protected]) if the file is less than 10 MB.

Ads may be submitted on CD-ROM. WinZip and Stuffit are the only acceptable compression techniques.

For disks and/or proofs, please send to: American Medical Communications Ari Mihos 630 Madison Avenue, 2nd Floor Manalapan, NJ 07726 732-490-5530

Closing DatesACC.17 Expo Daily Day 1, 2 and 3:

Ad space . . . . . . . Jan. 25, 2017

Final ad artwork . . . Feb. 8, 2017

Industry-Expert Theater 1#24100

Industry-Expert Theater 2#25078

Innovation Stage#24046

Interactive Learning Labs#13016, #17021

Patient Engagement Pavilion#24035

Sim Center#24062

SEE THE FULL SCHEDULE INSIDE

4 Interview with ACC President

8 Critical Care Cardiology

12 Diabetes Research

13 HF Learning Pathway

CONTINUE YOUR EDUCATIONAL

EXPERIENCE WITH

ACC.17 LEARNING

DESTINATIONS

Non-Statin Treatment: The Place of PCSK9 Inhibitors For LDL-C Reduction

Solutions and questions came with the approval of alirocumab and evolocumab, the first two agents in a new class of proprotein convertase

subtilisin/kexin 9 (PCSK9) inhibitors, by the U.S. Food and Drug Administration last summer. Approved as adjunctive treatment for persistently elevated levels of LDL-C despite diet and maximally-tolerated statin therapy, these drugs are an important solution for selected patients, including adults with familial hyper-cholesterolemia or clinical atherosclerotic cardiovas-cular disease with residual risk.

Key among the questions is whether the substantial reduction in LDL-C produced by these drugs will also reduce cardiovascular events and save lives and what is the long-term safety profile, along with the appropriate treatment algorithm and the impact of their cost.

“We are eagerly looking forward to the results of the larger outcomes trials to have a better

understanding of the risk-benefit profile of the PCSK9 inhibitors,” says Christie Ballantyne, MD, FACC, chair and moderator of ACC’s LDL: Address the Risk Think

Tank, which took place this past September at ACC’s Heart House in Washington, DC. The event-driven FOURIER trial with evolocumab is anticipated to be completed in 2017 and the ODYSSEY study with alirocumab in 2018.

The approval studies demonstrated good tolerability and efficacy, with reductions in LDL-C ranging from 47-56 percent with evolocumab and from 39-62 percent with alirocumab, compared with placebo, on top of maximally-tolerated statin therapy and diet.

“Statins remain the mainstay of treatment,” says Ballantyne, and have the bulk of the evidence for lowering LDL-C and hard outcomes. The emphasis continues to be matching the intensity of statin treatment to the patient’s level of risk, as first recommended by the 2013 ACC/American Heart Association guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk, which identified four statin benefit groups.

The PCSK9 inhibitors provide a more potent drug for combination therapy with a statin, providing a greater reduction in LDL-C than the modest (~20 percent) reduction achieved with ezetimibe added to the moderate-intensity simvastatin in the IMPROVE-IT trial in high-risk patients who had an acute coronary syndromes. This was the first trial to show a benefit with the addition of a non-statin drug and provided further evidence for the LDL hypothesis of clinical benefit with lower levels of LDL-C.

For high-risk patients with clinical atherosclerotic disease and familial hypercholesterolemia, including those with true statin intolerance, “these drugs are a breakthrough that provide the first new treatment for elevated LDL-C in decades,” says Kim Birtcher, MS, PharmD, AACC, chair of the ACC’s LDL: Address the Risk Oversight Workgroup. In the absence of the hard data needed from the randomized, controlled trials with these drugs, there are preliminary data from the approval study with evolocumab suggesting a reduction in cardiovascular events and safety, although the follow-up was only 18 months.

In terms of long-term safety, experts will be looking for signals of possible downsides of lowering LDL-C to much lower levels than previously achieved. There are concerns that if LDL-C is too low there could be negative neurocognitive effects and an increased risk of diabetes and hemorrhagic stroke.

The College has published an Expert Consensus Decision Pathway on the role of non-statin therapies for LCL-C lowering in the management of ASCVD risk to complement the guidelines and bridge the gaps in clinical guidance is being developed.

continued on page 1

ACC.17 Expo Daily 66TH ANNUAL SCIENTIFIC

SESSION & EXPO

WASHINGTON, DC

FRIDAYMARCH 17, 2017

TODAY’S

EXPO HOURS9:30 a.m. – 4:45 p.m.

TODAY’S

EXPO BREAKS

9:30 a.m. – 10:45 a.m.12:15 p.m. – 2:00 p.m.3:30 p.m. – 4:45 p.m.

Bleed Non-Bleed

Full Page Ad:

Trim Size: 8.375 x 10.5 in. 7.625 x 9.75 in.




Trim Size: 8.375 x 5.25 in. 7.625 x 4.5 in.



Quarter Page Ad:

Trim Size: 4 x 5.25 in. 3.5 x 4.5 in.



Bleed Non-Bleed

Full Page Ad:

Trim Size: 8.375 x 10.5 in. 7.625 x 9.75 in.




Trim Size: 8.375 x 5.25 in. 7.625 x 4.5 in.



Quarter Page Ad:

Trim Size: 4 x 5.25 in. 3.5 x 4.5 in.



ACC.17 Update eNewslettersRecipients get a preview of pertinent ACC.17 informa-tion, including registration dates, keynote speakers, etc.

RecipientsAverage Number of Recipients: 35,000 per email

Each preview email is sent to all ACC members, and current and past ACC annual meeting attendees

20% Average Open Rate

DistributionBi-weekly . . . . . . . Sept. 2016 – March 2017

Advertising Opportunities

Skyscraper . . . . . . . . . . . . . . . . . . . 160 x 600Leaderboard . . . . . . . . . . . . . . . . . . 728 x 90Mobile* . . . . . . . . . . . . . . . . . . . . . .300 x 250Net Cost . . . . . . . . . $3,500 per banner slot *no additional cost for mobile placement

Thumb DriveIdeal opportunity to reach ACC.17 attendees and cardiologists through an educational tool that will be referred to repeatedly, during and after ACC’s Annual Scientific Session & Expo. 5,000 thumb drives to be distributed from the ACC Central booth. Attendees must present a voucher received from the sponsor booth.

• Single-Sponsored

• Full text of the abstracts

• Sponsor recognition on sleeve

Net cost .........................................$63,500

Closing DatesAd space .............................Jan. 25, 2017 Final ad artwork ..................Feb. 8, 2017

Specs

Trisha Laramee [email protected]

Adam Sansolo [email protected]

Jeffrey Douglas [email protected]

YOUR AD

HERE

YOUR AD HERE

NCDR.17 Registration Issue NCDR.17 attracts over 1,500 registry profes-sionals, quality experts, cardiovascular administrators and physicians from across the country. Content will include cardio-vascular trends and hot topics related to the College’s eight hospital-based and two outpatient-based registries. Articles related to public reporting, quality improvement and accreditation will also be included.

Included in all registration bags.

Ad Size

Full Page Ad $4,000

Half Page Ad (Horizontal or Vertical)

$3,500

Quarter Page Ad $2,500

Cover 2 $2,200 premium



Rates

ACC.17 Advertising Opportunities - J....

Documents

Transcript of ACC.17 Advertising Opportunities - J....